Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2007-02-13
2007-02-13
Helms, Larry R. (Department: 1643)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C424S133100, C435S069600, C530S387300, C536S023530
Reexamination Certificate
active
10110141
ABSTRACT:
The present invention relates to compositions and methods of producing higher affinity molecules, and in particular, higher affinity antibodies. Specifically, the invention contemplates methods of mutagenesis to create a population of oligonucleotides coding for altered polypeptides that are expressed in a host cell and subsequently sequenced to determine the amino acid determinants conferring higher affinity.
REFERENCES:
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter
patent: 5264563 (1993-11-01), Huse
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5523388 (1996-06-01), Huse
patent: 5585089 (1996-12-01), Queen et al.
patent: 5589573 (1996-12-01), Hagiwara et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5723323 (1998-03-01), Kauffman et al.
patent: 5814476 (1998-09-01), Kauffman et al.
patent: 5817483 (1998-10-01), Kauffman et al.
patent: 5824514 (1998-10-01), Kauffman et al.
patent: 5871974 (1999-02-01), Huse
patent: 5976862 (1999-11-01), Kauffman et al.
patent: 5977322 (1999-11-01), Marks et al.
patent: 6096551 (2000-08-01), Barbas et al.
patent: 6312693 (2001-11-01), Aruffo et al.
patent: 2125240 (1995-12-01), None
patent: 2152240 (1995-12-01), None
patent: 0 451 216 (1991-10-01), None
patent: 0 519 596 (1992-05-01), None
patent: 0 682 040 (1995-11-01), None
patent: 0 939 127 (1999-09-01), None
patent: WO 99/42075 (1999-08-01), None
Glaser et al. Journal of Immunology, 1992, 149 (12):3903-3913.
Huse et al. Inter. Rev. Immunol., 1993, 10:129-137.
Yelton et al. Journal of Immunology, 1995, 155:1994-2004.
Rebar et al. Science. 1994. 263; 671-673.
Söderlind et al. Gene. 160:269-272, 1995.
Paul W. E., Fundamental Immunology, 3rded 1993, pp. 292-295.
Barbas et al. Proc. Natl. Acad. Sci. USA, 89:4457-4461, 1992.
Yang et al. Journal of Molecular biology 254:392-403, 1995.
Wu et al. Journal of Molecular Biology, 294:151-162, 1999.
Amit et al., “Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 A Resolution,”Science233:747-753 (1986).
Baca et al., “Antibody humanization using monovalent phage display,”J. Biol Chem272:10678-84 (1997).
Baca et al., “Phage display of a catalytic antibody to optimize affinity for transition-state analog binding,”Proc Natl Acad Sci USA94:10063-10068 (1997).
Chothia et. al., “Conformations of immunoglobulin hypervariable regions,”Nature342:877-883 (1989).
Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins,”J. Mol. Biol. 196:901-917 (1987).
Durie et. al., “Antibody to the Ligand of CD40, gp39, Blocks the Occurrence of the Acute and Chronic Forms of Graft-vs-Host Disease,”J Clin Invest94:1333-1338 (1994).
Foote and Winter, “Antibody framework residues affecting the conformation of the hypervariable loops,”J Mol Biol224:487-499 (1992).
Foy et al., “Immune Regulation by CD40 and its Ligand GP39,”Annu Rev Immunol14:591-617 (1996).
Francisco et al., “In Vivo Efficacy and Toxicity of a single-Chain Immunotoxin Targeted to CD40,”Blood89:4493-4500 (1997).
Francisco et al., “Activity of a single-Chain Immunotoxin that Selectively Kills Lymphoma and other B-Lineage Cells expressing the CD40 Antigen,”Cancer Res55:3099-3104 (1995).
Glaser et al., “Antibody engineering by codon-based mutagenesis in a filamentous phage vector system,”J. Immunology149:3903-3913 (1992).
Harris & Bajorath, “Profiles for the analysis of immunoglobulin sequences: Comparison of V gene subgroups,”Prot Sci4:306-310 (1995).
Herren et al., “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues,” J Molecular Biology 294:151-162 (1999).
Huston et al., “Antigen Recognition and Targeted Delivery by the Single-Chain Fv,”Cell Biophysics, 22:189-224 (1993).
Irving et al., “Affinity maturation of recombinant antibodies usingE. colimutator cells,” Immunotechnology 2:127-143 (1996).
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,”Nature321:522-525.
Jönsson and Malmquist, “Real Time Biospecific Interaction Analysis,”Advances in Biosnsors, 2:291-336 (1992).
Kabat et al.,Sequences of protein of immunological interest., (5th Ed) Washington DC: United States Department of Health and Human Services (1991).
Kabat et al., “Unusual distributions of amino acids in compementarity determining (hypervariable) segments of heavy and light chains of immunoglobulins and their possible roles in specificity of antibody combining sites,”J. Biol. Chem. 252, 6609-6616 (1977).
Kristensson et. al., “Humanization of a murine antibody against cryptococcus neoformans polysaccharide using a novel approach,”Vaccines 95, pp. 39-43 Cold Springs Harbor Laboratory Press, Cold Spring Harbor, NY (1995).
Kunkel, “Rapid and Efficient site-specific mutagenesis without phenotypic selection,”Proc Natl. Acad Sci USA82:488-492 (1985).
MacCallum et al., “Antibody-antigen interactions: contact analysis and binding site topgraphy,”J. Mol. Biol. 262:732-745 (1996).
Mach et al., “Reduction of atherosclerosis in mice by inhibition of CD40 signalling,”Nature394:200-203 (1998).
Padlan, “A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties,”Mol Immunol28:489-498 (1991).
Padlan, “Anatomy of the antibody molecule,”Mol Immunol31:169-217 (1994).
Plückthun and Skerra, “Expression of Functional Antibody Fv and Fab Fragments inEscherichia coli,” Meth. Enzymol., 178:497-515 (1989).
Rader et al., “A phage display approach for repid antibody humanization: Designed combinatorial V gene libraries,”Proc Natl Acad Sci USA95:8910-8915 (1998).
Riechmann et al., “Reshaping human antibodies for therapy,”Nature332:323-327 (1988).
Rosok et al., “A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab,”J Biol Chem271:22611-22618.
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,”Proc Natl Acad Sci USA79:1979-1983 (1982).
Schier et al., “Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site,”J Mol Biol263:551-567 (1996).
Schreiber & Fersht, “Energetics of protein-protein interactions: Analysis of the barnase-barstar interface by single mutations and double mutant cycles,”J Mol Biol248:478-486 (1995).
Singer et al., “Optimal humanization of 1B4, an anti-CD 18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences,”J Immunol150:2844-2857 (1993).
Stamenkovic et al., “A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas,”EMBO J8(5): 1403-1410 (1989).
Studnicka et al., “Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity modulating residues,”Protein Eng7:805-814 (1994).
Thompson et al., “Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: Use of phage display to improve affinity and broaden strain reactivity,”J Mol Biol256:77-88 (1996).
Uckun et al., “Temporal Association of CD40 Antigen Expression with Discrete Stages of Human B-Cell Ontogeny and the Efficacy of Anti-CD40 Immunotoxins Against Clonogenic B-Lineage Acute Lymphoblastic Leukemia as Well as B-Lineage Non-Hodgkin's Lymphoma Cells,”Blood76(12):2449-2456 (1990).
Watkins et al., “Discovery of human antibodies to cell surface antigens by capture lift screening of phage-expressed antibody
Huse William D.
Watkins Jeffry D.
Wu Herren
Applied Molecular Evolution
Blanchard David J.
Helms Larry R.
Martinez Alejandro
Stewart Mark J.
LandOfFree
Methods of optimizing antibody variable region binding affinity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of optimizing antibody variable region binding affinity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of optimizing antibody variable region binding affinity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3831241